CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
Sorafenib +1 moredrug
Likely dose
Sorafenib 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00837876
NCT00837876Phase 2Completed
CompareCT.gov

A Phase II Trial of Sorafenib and Erlotinib in Unresectable Pancreatic Cancer

Vanderbilt-Ingram Cancer Center·interventional·Posted Feb 6, 2009·Updated Jun 25, 2014

In Brief

A Phase 2 clinical trial evaluating Sorafenib and Erlotinb for Pancreatic Cancer. Completed, enrolled 37 participants across 6 sites.

Detailed Summary

RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sorafenib together with erlotinib works in treating patients with pancreatic cancer that cannot be removed by surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 6, 2009
Enrollment StartOct 1, 2008
Primary CompletionApr 1, 2011
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 17.4 years ago

Interventions

Sorafenibdrug

400 mg taken by mouth 1 time per day.

Erlotinbdrug

150 mg taken by mouth 1 time per day.